Pharmacy and Pharmaceutical Sciences Commons^™

Serotonin Syndrome And/Or Opioid Withdrawal After The First Dose Of Naltrexone Hcl/Bupropion Hcl: An Observational Study, Stefanie J. Logothetis

Pharmaceutical Sciences ETDs

In 2014, the Food and Drug Administration approved naltrexone HCl/bupropion HCl, a combination of an antidepressant and an opioid antagonist for chronic weight management therapy. Concurrent use of antidepressants and opioids has the potential to cause drug interactions involving serotonin syndrome. Our primary objective is to identify cases of serotonin syndrome and/or opioid withdrawal after initiation of naltrexone HCl/bupropion HCl. Our secondary objective is to assess which specific opioids are more likely to cause a drug interaction with naltrexone HCl/bupropion HCl. We performed an observational study by reviewing cases in the RADARS^® database from January 2014 through December 2018. …